Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
Cantor Fitzgerald Reiterates Overweight Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...
Vertex stock price target cut to $533 by Piper Sandler
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...
Cystic Fibrosis Therapeutics Market Booming Worldwide With Analysis, Growth, Upcoming Trend & Future Scope By 2033
The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...
Investing4d
Cantor Fitzgerald maintains Vertex stock Overweight rating
Vertex Pharmaceuticals (NASDAQ ... FDA's approval of Alyftrek and the expanded approval for the cystic fibrosis drug Trikafta. However, the FDA also updated Trikafta's safety information, warning ...
Seeking Alpha4d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
BioPharma Dive6d
Sionna, Odyssey join queue of biotechs testing investors’ IPO interest
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...